Product Images Xulane
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 23 images provide visual information about the product associated with Xulane NDC 0378-3340 by Mylan Pharmaceuticals Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Chance of Getting Pregnant - image 01
This text seems to provide information about birth control methods and their effectiveness in preventing pregnancy. It mentions different methods, such as implants, injections, intrauterine devices, birth control pills, skin patches, vaginal rings, condoms, diaphragms, and spermicides. It also includes statistics on the number of pregnancies per 100 women in a year for different methods and suggests abstaining from sex during the most fertile days of the monthly cycle as a method of birth control.*
Choosing a place on the body for the patch - image 02
How to apply the patch Figure 01 - image 03
How to apply the patch Figure 02 - image 04
How to apply the patch Figure 03 - image 05
How to apply the patch Figure 04 - image 06
Figure 1: Likelihood of Developing a VTE Within One Year Among Pregnant and Non-Pregnant Women - image 07
Norelgestromin and Ethinyl Estradiol Structural Formula - image 08
norelgestromin and ethinyl estradiol are two hormones used together in various forms of hormonal birth control, such as the birth control patch. They work by preventing ovulation and thickening the cervical mucus to prevent sperm from reaching the egg.*
Figure 2: Mean Serum NGMN Concentrations (ng/mL) in Healthy Female Volunteers Following Application of Norelgestromin and Ethinyl Estradiol Transdermal System on the Buttock for Three Consecutive Cycles (Vertical arrow indicates time of patch removal) - image 09
Figure 3: Mean Serum EE Concentrations (pg/mL) in Healthy Female Volunteers Following Application of Norelgestromin and Ethinyl Estradiol Transdermal System on the Buttock for Three Consecutive Cycles (Vertical arrow indicates time of patch removal.) - image 10
Figure 4: Mean Serum Concentration-Time Profiles of NGMN Following Once-Daily Administration of an Oral Contraceptive for Two Cycles or Application of Norelgestromin and Ethinyl Estradiol Transdermal System for Two Cycles to the Buttock in Healthy Female Volunteers. [Oral contraceptive: Cycle 2, Days 15 to 21, Norelgestromin and Ethinyl Estradiol Transdermal System: Cycle 2, Week 3] - image 11
![Figure 4: Mean Serum Concentration-Time Profiles of NGMN Following Once-Daily Administration of an Oral Contraceptive for Two Cycles or Application of Norelgestromin and Ethinyl Estradiol Transdermal System for Two Cycles to the Buttock in Healthy Female Volunteers. [Oral contraceptive: Cycle 2, Days 15 to 21, Norelgestromin and Ethinyl Estradiol Transdermal System: Cycle 2, Week 3] - image 11](https://ndclist.com/assets/spl/images/f7848550-086a-43d8-8ae5-047f4b9e4382/image-11.jpg "image-11.jpg")
Figure 5: Mean Serum Concentration-Time Profiles of EE Following Once-Daily Administration of an Oral Contraceptive for Two Cycles or Application of Norelgestromin and Ethinyl Estradiol Transdermal System for Two Cycles to the Buttock in Healthy Female Volunteers. [Oral contraceptive: Cycle 2, Days 15 to 21, Norelgestromin and Ethinyl Estradiol Transdermal System: Cycle 2, Week 3] - image 12
![Figure 5: Mean Serum Concentration-Time Profiles of EE Following Once-Daily Administration of an Oral Contraceptive for Two Cycles or Application of Norelgestromin and Ethinyl Estradiol Transdermal System for Two Cycles to the Buttock in Healthy Female Volunteers. [Oral contraceptive: Cycle 2, Days 15 to 21, Norelgestromin and Ethinyl Estradiol Transdermal System: Cycle 2, Week 3] - image 12](https://ndclist.com/assets/spl/images/f7848550-086a-43d8-8ae5-047f4b9e4382/image-12.jpg "image-12.jpg")
Xulane Transdermal System 150/35 mcg per day Carton - image 13
Xulanee NoC 0576-3340-53 is a transdermal system used to prevent pregnancy. It contains norelgestromin and ethinyl estradiol and must be stored at controlled room temperature. Each pack contains a pouch to be used daily that delivers 150/35 mcg per day. It does not protect against sexually transmitted diseases. Lot and Exp prompts and/or Serialization are found in the area mentioned.*
Patch Calendar - image 14
Likelihood of Developing a Serious Blood Clot (Venous Thromboembolism [VTE]) - image 15
![Likelihood of Developing a Serious Blood Clot (Venous Thromboembolism [VTE]) - image 15](https://ndclist.com/assets/spl/images/f7848550-086a-43d8-8ae5-047f4b9e4382/image-15.jpg "image-15.jpg")
This text appears to be discussing the risks of CHC (combination hormonal contraception) and pregnancy after the postpartum period (13 weeks after giving birth). It provides pregnancy data based on the actual duration of pregnancy and cites a model that assumes pregnancy duration is nine months, indicating a rate of 7 to 27 per 10,000 Women Years (WY).*
Instructions for Use Figure A - image 16
Instructions for Use Figure B - image 17
Instructions for Use Step 1 - image 18
Instructions for Use Step 2 Figure 1 - image 19
Instructions for Use Step 2 Figure 2 - image 20
Instructions for Use Step 2 Figure 3 - image 21
Instructions for Use Step 2 Figure 4 - image 22
image 23
This is a list of different studies related to women's health and contraceptive use. It includes the name of the study, the year it was conducted, and whether it refers to ever or current use of contraceptives. The text at the bottom does not provide any useful information and appears to be unrelated.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.